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Summary  Active  surveillance  cultures  for  multidrug-resistant  (MDR)  gram-
negative  bacteria  is  one  strategy  to  control  outbreaks.  The  objectives  of  the  study
are  to  evaluate  the  prevalence  of  Acinetobacter  colonization  and  to  compare  con-
ventional  culture  and  in-house  developed  PCR  based  method.  Swabs  were  collected
from  patients  transferred  from  another  organization  or  were  admitted  to  the  inten-
sive  care  units.  Swabs  were  cultured  by  conventional  method  and  were  tested  using
in-house  LightCycler® 2.0  real-time  PCR  method.  Of  449  tested  samples,  the  major-
ity  came  from  cardiac  step  down  unit  (188,  42%),  male  medical  ﬂoor  (80;  18%),
and  coronary  care  unit  (66;  13.4%).  Of  the  total  specimens,  14  (3%)  were  posi-
tive  by  PCR  and  12  (2.6%)  were  positive  by  routine  cultures.  The  positivity  rates
among  wounds,  respiratory,  perineal,  and  nasal  samples  were  3.2%,  9.7%,  4.6%  and
0.8%  respectively.  Two  positive  samples  by  PCR  were  negative  by  routine  culture.
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The  overall  concordance  rate  was  99.5%  and  the  positive  concordance  rate  was  85.7%.
The  current  study  revealed  a  low  prevalence  of  MDR  Acinetobacter  among  the  studied
ler® 2.0  PCR  produced  comparable  positive  results  to  routine
dulaziz  University  for  Health  Sciences.  Published  by  Elsevier
ed.
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PCR  ampliﬁcations  were  carried  out  in  10-l  vol-
umes  containing  2.5  l  of  template  DNA  as  shown
in Table  1.  The  PCR  conditions  of  the  assay  was  aspopulation.  The  LightCyc
cultures.
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cinetobacter  spp.  in  general  and  Acinetobacter
aumannii in  particular  are  increasingly  recog-
ized pathogens  in  the  healthcare  setting  leading
o healthcare  associated  infections  [1—3].  The
mergence of  multi-drug  resistant  (MDR)  Acineto-
acter  is of  particular  importance  and  necessitates
he development  of  rapid  and  sensitive  molecu-
ar detection  methods  to  institute  the  appropriate
herapeutic and  infection  control  measures.  Such
ethodology  may  rely  on  PCR  or  loop-mediated
sothermal  ampliﬁcation  (LAMP)  assay  [4—6].  In
audi Arabia,  many  studies  showed  high  percent-
ge of  carbapenem  resistant  A.  baumannii  [7—9].
ctive surveillance  cultures  for  multidrug-resistant
MDR) gram-negative  bacteria  is  one  strategy  to
ontrol outbreaks  among  patients  in  intensive  care
nits and  patients  transferred  from  facilities  with
igh prevalence  rates  of  MDR  organisms  [10,11].
he effectiveness  of  screening  cultures  for  the
etection of  MDR  Acinetobacter  was  55%  even  if  six
amples were  obtained  [12].
We preemptively  developed  a  screening  pro-
ram to  screen  patients  admitted  to  the  intensive
are unit  and  those  admitted  from  other  hospitals.
hose patients  were  put  on  contact  isolations  and
creened  for  Acinetobacter. Since,  routine  cultures
ake  longtime  for  the  results;  we  sought  to  develop
 rapid  method  for  the  detection  of  Acinetobacter
pp. and  to  evaluate  the  prevalence  of  Acinetobac-
er among  this  cohort  of  patients.
aterials and methods
his  is  a  prospective  study  in  a  general  hospital  with
50 beds.  Swabs  were  obtained  from  the  nose  and
ounds.  A  total  of  449  different  multi-site  swabs
ere obtained  between  January  and  July  2014.
aboratory processing and culture methodshe  swabs  were  inoculated  on  Blood  agar  plate  and
HROMACIN  Acinetobacter  selective  agar  (Saudi
f
p
prepared  Media  laboratory  SPML).  Identiﬁcation
nd antibiotic  resistance  testing  were  done  after
4 h  of  incubation  at  37 ◦C and  5%  CO2 using  Vitek2
ystem (BioMérieux).  MDR  was  deﬁned  as  resis-
ance  to  more  than  two  of  the  following  classes:
ntipseudomonal  cephalosporins,  antipseu-
omonal carbapenems,  ampicillin/sulbactam,
uoroquinolones,  and  aminoglycosides  [13].
NA extraction
NA  was  extracted  using  the  MagNA-Pure-Compact-
ystem  (Roche  Diagnostics,  Mannheim,  Germany),
ccording  to  the  manufacturer’s  instructions.  The
wabs were  broken  into  1.5  Eppendorf  tube,  and
 ml  of  sterile  0.9%  NaCl  was  added  and  the  mix-
ure was  vortexed  vigorously.  A  total  of  400  l  of  the
ample suspension  was  pipetted  into  MagNa  pure
ample tube  and  DNA  extraction  was  performed
sing DNA-bacteria  protocol.  The  DNA  sample  was
luted in  50  l  total  volume.
rimer design
he  primers  and  probes  targeting  16S  RNA  sequence
f Acinetobacter  spp.  were  designed  by  TIB  Molbiol
Syntheselabor  GmbH,  Eresburgstr,  Berlin).  The
orward primer  was  Acineto  S:  5-ACAgCgATg-
gATgCTAA-3  and  the  reverse  primer  was:
cineto B:  5-TATTCACCgCggCATT-3.  To  increase  the
peciﬁcity of  the  PCR,  two  internal  oligonucleotide
ybridization  probes:  Acineto  FLU  probe:  5-
TgCAgACTCCAATCCgg—–FL  (18  bp,  Tm  =  56.3)  and
CRED640-CTACgATCggCTTTTTgAgAT—–PH  (21  bp,
m =  54.5)  were  added.  The  size  of  the  amplicon
as 115  bp.
CR ampliﬁcationollows:  after  10  min  at  95 ◦C  for  FastStart  Taq  DNA
olymerase  activation,  30  ampliﬁcation  cycles  were
erformed,  each  with  5  s denaturation  at  95 ◦C,
126  A.A.  Rabaan  et  al.
Table  1  Results  of  routine  cultures  and  PCR  testing.
Acinetobacter  MDR  Acinetobacter  Negative  culture  Total
PCR  positive  3  9  2  14
PCR  negative  0  0  435  435
Total  3  9  437  449
Lower limit of detection of the real time
PCR assay
The  lower  dilution  (150  CFU/swab)  showing  posi-
tive results  in  all  four  replicates  was  considered  the
analytical sensitivity.
Epidemiology of  Acinetobacter
The  majority  of  the  samples  came  from  cardiac  step
down unit  (188,  42%),  male  medical  ﬂoor  (80;  18%),
and coronary  care  unit  (66;  13.4%).  The  majority  of
patients were  male  (61.7%).  Of  all  the  samples,  106
(23.6%) were  perineal  swabs  and  122  (27.2%)  were
nasal swabs.
Comparative study results
Of  the  total  specimens,  14  (3%;  95%  CI:  1.2—4.1)
were positive  by  PCR  and  12  (2.6%;  95%  CI:  1.5—4.7)
were positive  by  routine  cultures  (P  value  = 0.84).
The positivity  rates  among  wounds,  respiratory,
perineal, and  nasal  samples  were  3.2%,  9.7%,
4.6% and  0.8%  respectively.  There  were  2  positive
samples by  PCR  and  were  negative  by  routine  cul-
ture (Table  1).  The  overall  concordance  rate  was
99.5% and  the  positive  concordance  rate  was  85.7%
(Table  2). The  two  PCR  positive  culture  negative
samples were  sub-cultured  on  BA  and  screened
again for  the  presence  of  Acinetobacter.  Both  sam-
ples grew  Acinetobacter  colonies.
Table  2  Concordance  Rate  between  the  results  of
routine  cultures  and  PCR  testing.
Routine  culture
Positive  Negative  Total
Positive  12  2  14Fisher’s exact test: two-tailed P value equals 0.8427.
5  s  annealing  at  60 ◦C  and  15  s  elongation  at  72 ◦C
on a  LightCycler® 2.0  instrument.  After  ampliﬁ-
cation, a  melting  curve  analysis  was  completed
after 20  s  denaturation  at  95 ◦C.  Samples  were  incu-
bated at  56 ◦C  for  20  s  by  continuous  heating  to
85 ◦C  with  a  slope  of  0.2 ◦C/s.  Samples  from  each
strain were  diluted,  from  isolated  colony  to  approx-
imately  0.5  McFarland.  A  total  of  400  l  of  the
suspension was  used  to  extract  the  DNA.  Acineto-
bacter ATCC#BAA747  was  diluted  to  approximately
0.5 McFarland.  The  suspension  was  diluted  to  reach
approximately  100—150  CFU/swab.  Each  dilution
was run  in  replicates  of  four  and  adsorbed  onto
Copan swab  (Copan  139C;  Copan  Italia  SPA,  Brescia,
Italy).
Results
Analytical speciﬁcity of the real time PCR
assay
The  primers  and  probes  were  speciﬁc  for  16S  RNA
sequence  Acinetobacter  spp.  A  total  of  72  ATCC
strains were  used  to  evaluate  the  cross-reactivity.
These included  Streptococcus  pneumoniae  ATCC
49619, Klebsiella  pneumoniae  ATCC  700603,  Strep-
tococcus  agalactiae  ATCC  12386,  Streptococcus
pyogenes  ATCC  19615,  Staphylococcus  epidermidis
ATCC 12228,  Haemophilus  inﬂuenzeae  ATCC  1011,
Escherichia  coli  ATCC  25922,  Pseudomonas  aerogi-
nosa ATCC  27853,  Enterococcus  faecalis  ATCC
29217, and  Acinetobacter  ATCC#BAA747.  All  bac-
terial strains  and  human  DNA  were  tested  and
revealed no  signal  ampliﬁcation,  indicating  that  the
assay is  speciﬁc.
Melting curve analysis
Melting  curve  analysis  of  Acinetobacter  spp.  ampli-
ﬁed PCR  products  revealed  a  single  distinct  melting
◦peak at  a  mean  of  61.52 C  (±2SD)  for  all  tested
ATCC and  culture  positive  strains.  The  expected
size of  the  PCR  product  was  conﬁrmed  by  gel  elec-
trophoresis  and  determined  as  115  bp.
PCR Negative  0  435  435
Total  12  437  449
Positive concordance rate 12/14 = 85.7%.
Overall concordance rate 437/449 = 97.3%.
EA
O
A
s
D
I
a
S
t
p
a
A
8
r
A
c
t
a
w
s
a
b
b
m
a
t
o
a
s
a
s
s
a
t
t
m
s
p
s
o
r
o
s
b
T
l
g
t
t
s
i
o
s
c
P
A
i
t
I
g
o
p
c
F
N
C
N
E
T
A
Rpidemiology  and  detection  of  acinetobacter  
ntibiotic susceptibility
f  the  12  culture  positive  samples,  9  (75%)  had  MDR
cinetobacter  and  this  represents  2%  of  all  tested
amples.
iscussion
n  this  study,  we  compared  the  performance  of
n in-house  LightCycler® 2.0  assay  (Roche  Applied
cience) and  a  standard  culture  method  for  detec-
ion of  Acinetobacter  from  452  swabs.  The  overall
ositive  rate  for  Acinetobacter  was  about  3%  of
ll tested  samples.  Another  study  from  two  Saudi
rabian hospitals  utilized  565  rectal  swabs  and
.3% showed  Acinetobacter  spp.  [14]. In  the  cur-
ent study,  2%  of  the  total  samples  were  MDR
cinetobacter and  represented  75%  of  the  positive
ultures.  In  the  same  institute,  MDR  Acinetobac-
er was  observed  in  14—35.8%  previously  [15]. In
 study  of  17,760  fecal  specimens,  1.9%  specimens
ere MDR  Acinetobacter  [16]  and  6.2%  in  another
tudy [14].  This  is in  contrast  to  a  recent  study  from
 nursing  home  where  25  of  168  (15%)  had  MDR  A.
aumannii  [17].
The  best  methods  for  active  screening  and  the
est specimen  to  detect  colonization  with  A.  bau-
annii are  not  known  [18].  In  the  current  study,
 higher  percentage  of  positivity  for  Acinetobac-
er was  among  throat  samples  (9.7%).  In  a  study
f carbapenem-resistant  A.  baumannii  screening
mong known  positive  patients,  the  most  frequent
ites  of  isolation  of  this  organism  were  tracheal
spirates (80%),  rectal  specimens  (69%),  sternal
kin swabs  (52%),  and  urine  (25%)  [19].  In  another
tudy,  prevalence  of  Acinetobacter  was  4.9%,  6.5%
nd 4.2%  from  rectal  swabs,  pharyngeal  swabs,  and
racheal aspirates,  in  patients  on  mechanical  ven-
ilation [20].
Active  screening  for  the  detection  of  A.  bau-
annii was  mathematically  calculated  to  be  cost
aving (19—53%  reduction  in  mean  hospital  cost  per
atient) except  at  a  carrier  prevalence  of  ≤2%  and
creening  test  sensitivity  of  ≤55%  [21].  Given  the
verall prevalence  of  Acinetobacter  spp  in  the  cur-
ent study  of  3%,  active  screening  is  cost  effective
nly for  those  patients  who  are  at  high  risk  of  acqui-
ition  of  Acinetobacter  in  our  population.
The LightCycler® 2.0  PCR  produced  compara-
le positive  results  (3%)  to  routine  cultures  (2.6%).
he failure  of  the  culture  to  identify  two  samples
ikely related  to  the  overgrowth  of other  microor-
anisms. Thus,  the  PCR  methodology  could  be  used
o screen  patients  for  Acinetobacter  and  allow  fast
urnaround  time  of  2  h  compared  to  3—5  days  by127
tandard  culture  method.  This  has  an  impact  on
nfection  control  and  isolation  of  infected  or  col-
nized  patients.  However,  a positive  PCR  in  this
tudy  could  not  differentiate  between  MDR  and  sus-
eptible Acinetobacter.  Thus,  MDR  Acinetobacter
CR detection  is  desirable  when  the  prevalence  of
cinetobacter  is  high.
The  limitation  of  the  current  study  includes:
nability to  differentiate  different  species  of  Acine-
obacter  and  inability  to  detect  MDR  Acinetobacter.
n areas  with  low  prevalence  of Acinetobacter  in
eneral,  the  use  of  the  current  PCR  methodol-
gy would  provide  rapid  identiﬁcation  of  colonized
atients and  those  then  could  be  screened  using
onventional method.
unding
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